Vorinostat (suberoylanilide hydroxamic acid; SAHA) is a histone deacetylase inhibitor (HDACi) approved in the clinics for the treatment of T-cell lymphoma and with the potential to be effective also in breast cancer. We investigated the responsiveness to SAHA in human breast primary tumors and cancer cell lines.
Redox-mediated suberoylanilide hydroxamic acid sensitivity in breast cancer / F. Chiaradonna, I. Barozzi, C. Miccolo, G. Bucci, R. Palorini, L. Fornasari, O.A. Botrugno, G. Pruneri, M. Masullo, A. Passafaro, V.E. Galimberti, V.R. Fantin, V.M. Richon, S. Pece, G. Viale, P.P. Di Fiore, G. Draetta, P.G. Pelicci, S. Minucci, S. Chiocca. - In: ANTIOXIDANTS & REDOX SIGNALING. - ISSN 1523-0864. - 23:1(2015 Jul 01), pp. 15-29. [10.1089/ars.2014.6189]
Redox-mediated suberoylanilide hydroxamic acid sensitivity in breast cancer
G. Bucci;G. Pruneri;S. Pece;G. Viale;P.P. Di Fiore;P.G. Pelicci;S. MinucciPenultimo
;
2015
Abstract
Vorinostat (suberoylanilide hydroxamic acid; SAHA) is a histone deacetylase inhibitor (HDACi) approved in the clinics for the treatment of T-cell lymphoma and with the potential to be effective also in breast cancer. We investigated the responsiveness to SAHA in human breast primary tumors and cancer cell lines.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ars%2E2014%2E6189.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
2.62 MB
Formato
Adobe PDF
|
2.62 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
